Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.69 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.67 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | GLA | P06280 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.67 |
| ▸ | THPO | P40225 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | APEX1 | P27695 | 1/20 | 0.65 |
| ▸ | BLM | P54132 | 1/20 | 0.65 |
| ▸ | NLN | Q9BYT8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8234259 | 0.84 | CYP3A4 (0.57) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL13609239 | 0.83 | CYP3A4 (0.73) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL7962292 | 0.83 | CYP3A4 (0.73) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL18162806 | 0.83 | CYP3A4 (0.73) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL26576389 | 0.83 | HRH4 (0.56) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| Histidine SCHEMBL28093400 | 0.82 | CYP3A4 (0.93) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL5717709 | 0.81 | CYP3A4 (0.75) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| Histidine SCHEMBL19974306 | 0.81 | CYP3A4 (1.00) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| Histidine SCHEMBL388560 | 0.81 | CYP3A4 (1.00) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| D-Histidine SCHEMBL288043 | 0.81 | CYP3A4 (1.00) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017535-A1 | INHIBITORS OF ALDOSE REDUCTASE | BARCLAYS BANK PLC (GB) | 2022-01-20 | — | — | US | disclosed |
| US-20210277050-A1 | OPHTHALMIC COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE DISORDERS | CELLIX BIO PRIVATE LIMITED (IN) | 2021-09-09 | — | — | US | disclosed |
| US-8354383-B2 | 6,11-bridged biaryl macrolides | ENANTA PHARMACEUTICALS, INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-8273720-B2 | 6,11-bicyclolides: bridged biaryl macrolide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273720-B2 | 6,11-bicyclolides: bridged biaryl macrolide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-7785825-B2 | Compositions and methods for dehydration and cyclization of peptides, synthetic compounds, and lantibiotics | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2010-08-31 | — | — | US | disclosed |
| US-20090270457-A1 | 6,11-BICYCLOLIDES: BRIDGED BIARYL MACROLIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090270457-A1 | 6,11-BICYCLOLIDES: BRIDGED BIARYL MACROLIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090264380-A1 | 6,11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090118506-A1 | 6,11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
| US-20090075915-A1 | 6,11-BICYCLOLIDES: BRIDGED BIARYL MACROLIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075915-A1 | 6,11-BICYCLOLIDES: BRIDGED BIARYL MACROLIDE DERIVATIVES | CYP2B6, ABCB11, CYP2D6 | CYP3A4 19/4885SLC7A5 2041/4885HRH4 3325/4885 |
| US-20090270457-A1 | 6,11-BICYCLOLIDES: BRIDGED BIARYL MACROLIDE DERIVATIVES | CYP2B6, ABCB11, CYP2D6 | CYP3A4 19/4885SLC7A5 2041/4885HRH4 3325/4885 |
| US-20220017535-A1 | INHIBITORS OF ALDOSE REDUCTASE | PMM2, DPM1, BPGM | CYP3A4 2713/4885SLC7A5 4419/4885HRH4 3955/4885 |
| US-20090118506-A1 | 6,11-BRIDGED BIARYL MACROLIDES | CYP2B6, CYP2D6, ABCB11 | CYP3A4 18/4885SLC7A5 1562/4885HRH4 2447/4885 |
| US-20210277050-A1 | OPHTHALMIC COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE DISORDERS | F5, OR10J3, SHBG | CYP3A4 25/4885SLC7A5 2176/4885HRH4 1512/4885 |
| US-20090264380-A1 | 6,11-BRIDGED BIARYL MACROLIDES | CYP2B6, CYP2D6, ABCB11 | CYP3A4 16/4885SLC7A5 1641/4885HRH4 2415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.